Telix Pharmaceuticals (ASX:TLX) completed patient enrollment in the phase three BiPASS study of its prostate-specific membrane antigen positron emission tomography (PSMA-PET) imaging agents Gozellix and Illuccix for prostate cancer imaging in the pre-biopsy setting, with 350 patients enrolled in the US and Australia, according to a Wednesday Australian bourse filing.
The study seeks to evaluate whether the combination of magnetic resonance imaging and the imaging of prostate-specific membrane antigen with positron emission tomography/computed tomography with Telix's proprietary gallium-68-PSMA-PET agents can improve diagnostic accuracy, reduce unnecessary biopsies, or improve targeting of biopsy compared with current standard practice.
The firm also aligned with the US Food and Drug Administration on a new drug application pathway for BiPASS.
Its shares rose nearly 1% in recent trading on Wednesday.